StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Earnings

Zevra Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 8, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$37.80M
+44.8% on a year earlier
Adjusted EPS, Q3 FY2026
$0.26
-$0.01 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Zevra Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 8, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$37.80M+44.8%$0.26–Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$39.70M+53.3%$0.14$0.25Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$36.20M+77.5%$0.60$0.18Release
Q4 FY2025ended Dec 31, 2025Mar 9, 2026after the close$34.10M+184.2%$0.19–Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$26.10M+605.4%-$0.01–Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close$25.90M+488.6%$1.21-$0.06Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close$20.40M+500.0%-$0.06–Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025after the close$12.00M-9.1%-$0.67–Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024after the close$3.70M+27.6%––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close$4.40M-48.2%-$0.48–Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$3.40M+17.2%-$0.40–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Zevra Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Zevra Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Zevra Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Update
  5. Results
  6. Results
  7. Update
  8. Update
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?